MX345715B - Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. - Google Patents
Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa.Info
- Publication number
- MX345715B MX345715B MX2012000298A MX2012000298A MX345715B MX 345715 B MX345715 B MX 345715B MX 2012000298 A MX2012000298 A MX 2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A MX 345715 B MX345715 B MX 345715B
- Authority
- MX
- Mexico
- Prior art keywords
- tyrosine kinase
- binding domain
- extracellular
- allosteric inhibitor
- kinase receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un dominio de unión extracelular para un inhibidor alostérico, de tal manera que dicho dominio de unión se derive de un receptor de tirosina quinasa de transmembrana único. Más específicamente, la invención se refiere a un dominio extracelular derivado de un receptor de factor de crecimiento de fibroblastos (FGFR). Se refiere además a la utilización de este dominio para la identificación de dominios similares en la parte extracelular de otros receptores tirosina quinasa, y a un método de selección para la identificación de un compuesto pequeño inhibidor alostérico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290537A EP2270043A1 (en) | 2009-07-03 | 2009-07-03 | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| PCT/IB2010/053054 WO2011001413A1 (en) | 2009-07-03 | 2010-07-02 | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012000298A MX2012000298A (es) | 2013-05-30 |
| MX345715B true MX345715B (es) | 2017-02-13 |
Family
ID=41137351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000298A MX345715B (es) | 2009-07-03 | 2010-07-02 | Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9234025B2 (es) |
| EP (2) | EP2270043A1 (es) |
| JP (2) | JP6255156B2 (es) |
| KR (1) | KR101828092B1 (es) |
| CN (1) | CN102596991B (es) |
| AU (1) | AU2010267590B2 (es) |
| BR (1) | BR112012000029B8 (es) |
| CA (1) | CA2766972C (es) |
| DK (1) | DK2448964T3 (es) |
| ES (1) | ES2631452T3 (es) |
| HU (1) | HUE035052T2 (es) |
| IL (1) | IL217155B (es) |
| MX (1) | MX345715B (es) |
| MY (1) | MY158993A (es) |
| RU (1) | RU2604805C2 (es) |
| SG (2) | SG10201403778TA (es) |
| WO (1) | WO2011001413A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| WO2015127242A1 (en) | 2014-02-21 | 2015-08-27 | President And Fellows Of Harvard College | De novo design of allosteric proteins |
| CN106660997B (zh) | 2014-08-18 | 2019-05-21 | 卫材R&D管理有限公司 | 单环吡啶衍生物的盐及其晶体 |
| WO2018081534A1 (en) | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
| CN111107881A (zh) * | 2017-06-22 | 2020-05-05 | 密执安州立大学董事会 | 成纤维细胞生长因子受体2特异性肽试剂和方法 |
| EP3710483A4 (en) * | 2017-11-16 | 2021-10-20 | XL-protein GmbH | PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY |
| CA3091153A1 (en) | 2018-03-28 | 2019-10-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| CN113651662B (zh) * | 2020-12-31 | 2023-10-27 | 复旦大学附属华山医院 | 一种靶向fgfr的新型肿瘤pet分子探针及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522483A (en) * | 2000-05-11 | 2005-06-24 | Wyeth Corp | Structure of free regulator of G-protein signaling (RGS4) and methods of identifying agonists and antagonists using same |
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| WO2005066211A2 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| FR2865934B1 (fr) * | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
| JP2008501356A (ja) * | 2004-06-09 | 2008-01-24 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ | 神経幹細胞 |
| WO2006113602A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Trustees Of Michigan State University | Ascorbate binding peptides |
| FR2896247B1 (fr) | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| EP1891955A1 (en) * | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
-
2009
- 2009-07-03 EP EP09290537A patent/EP2270043A1/en not_active Withdrawn
-
2010
- 2010-07-02 HU HUE10734333A patent/HUE035052T2/en unknown
- 2010-07-02 US US13/379,822 patent/US9234025B2/en active Active
- 2010-07-02 WO PCT/IB2010/053054 patent/WO2011001413A1/en active Application Filing
- 2010-07-02 RU RU2012103542/10A patent/RU2604805C2/ru active
- 2010-07-02 KR KR1020127002920A patent/KR101828092B1/ko active IP Right Grant
- 2010-07-02 CA CA2766972A patent/CA2766972C/en active Active
- 2010-07-02 DK DK10734333.7T patent/DK2448964T3/en active
- 2010-07-02 EP EP10734333.7A patent/EP2448964B1/en active Active
- 2010-07-02 BR BR112012000029A patent/BR112012000029B8/pt active IP Right Grant
- 2010-07-02 SG SG10201403778TA patent/SG10201403778TA/en unknown
- 2010-07-02 SG SG2011097284A patent/SG177427A1/en unknown
- 2010-07-02 ES ES10734333.7T patent/ES2631452T3/es active Active
- 2010-07-02 JP JP2012518145A patent/JP6255156B2/ja active Active
- 2010-07-02 MX MX2012000298A patent/MX345715B/es active IP Right Grant
- 2010-07-02 MY MYPI2011006390A patent/MY158993A/en unknown
- 2010-07-02 AU AU2010267590A patent/AU2010267590B2/en active Active
- 2010-07-02 CN CN201080039710.5A patent/CN102596991B/zh active Active
-
2011
- 2011-12-22 IL IL217155A patent/IL217155B/en active IP Right Grant
-
2015
- 2015-11-30 US US14/954,301 patent/US20160193192A1/en not_active Abandoned
-
2016
- 2016-10-07 JP JP2016198682A patent/JP2017036305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY158993A (en) | 2016-11-30 |
| AU2010267590B2 (en) | 2016-08-04 |
| EP2448964A1 (en) | 2012-05-09 |
| IL217155B (en) | 2019-01-31 |
| SG10201403778TA (en) | 2014-10-30 |
| EP2270043A1 (en) | 2011-01-05 |
| AU2010267590A1 (en) | 2012-02-02 |
| WO2011001413A1 (en) | 2011-01-06 |
| CN102596991B (zh) | 2016-06-08 |
| SG177427A1 (en) | 2012-02-28 |
| CA2766972C (en) | 2019-03-05 |
| BR112012000029B1 (pt) | 2020-12-08 |
| US9234025B2 (en) | 2016-01-12 |
| KR101828092B1 (ko) | 2018-02-09 |
| RU2012103542A (ru) | 2013-08-10 |
| CN102596991A (zh) | 2012-07-18 |
| US20160193192A1 (en) | 2016-07-07 |
| DK2448964T3 (en) | 2017-07-24 |
| BR112012000029A2 (pt) | 2016-11-08 |
| BR112012000029B8 (pt) | 2021-05-25 |
| RU2604805C2 (ru) | 2016-12-10 |
| CA2766972A1 (en) | 2011-01-06 |
| JP6255156B2 (ja) | 2017-12-27 |
| KR20120093146A (ko) | 2012-08-22 |
| US20120094864A1 (en) | 2012-04-19 |
| JP2017036305A (ja) | 2017-02-16 |
| MX2012000298A (es) | 2013-05-30 |
| EP2448964B1 (en) | 2017-04-12 |
| HUE035052T2 (en) | 2018-05-02 |
| IL217155A0 (en) | 2012-02-29 |
| JP2012532121A (ja) | 2012-12-13 |
| ES2631452T3 (es) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY158993A (en) | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor | |
| IL194752A0 (en) | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk | |
| MY155621A (en) | Axl antibodies | |
| HK1216887A1 (zh) | 布魯頓酪氨酸激酶的抑制劑 | |
| BRPI0922224A2 (pt) | composições de inibidores de proteína tirosina quiinase receptora. | |
| IL208882A0 (en) | Inhibitors of protein tyrosine kinase activity | |
| TN2011000673A1 (en) | Bace inhibitors | |
| AP2012006166A0 (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors. | |
| EP2040546A4 (en) | TYROSINE KINASE INHIBITORS | |
| ZA201202552B (en) | Inhibitors of bruton's tyrosine kinase | |
| SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
| EP2484678A4 (en) | SUBSTITUTED 4- (ANILINO) DERIVATIVES QUINAZOLINE AS TYROSINE KINASE INHIBITORS | |
| PL2121687T3 (pl) | Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej | |
| EA201270350A1 (ru) | Способ идентификации и получения (r)-специфической омега-трансаминазы | |
| IL196337A0 (en) | Tyrosine kinase inhibitors | |
| WO2010070658A3 (en) | Improved process for the preparation of endothelin receptor antagonists | |
| CL2011000295A1 (es) | Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. | |
| MY157319A (en) | Inhibitors of protein tyrosine kinase activity | |
| MX2009012474A (es) | Compuestos de quinazolina. | |
| EP2247185A4 (en) | INHIBITORS OF TYROSINE KINASE | |
| MX2010002994A (es) | Dominios de fijacion del ligando de receptores nucleares en forma controlable y metodos que conllevan los mismos. | |
| DE602005019090D1 (de) | Pyrrolidin-2-on-Derivate zur Verwendung als DP1-Rezeptoragonisten | |
| WO2009124013A8 (en) | Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling | |
| EP2313517A4 (en) | TYROSINE KINASE RECEPTOR ASSAYS | |
| TH104263B (th) | สารยับยั้งของแอคติวิตี้ของโปรตีนไทโรซีนไคเนส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |